Cargando…

Antiangiogenic therapies in urogenital malignancies: Fiction or fact?

The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for s...

Descripción completa

Detalles Bibliográficos
Autores principales: Haidl, Friederike, Pfister, David, Heidenreich, Axel, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725505/
https://www.ncbi.nlm.nih.gov/pubmed/29250197
http://dx.doi.org/10.1007/s12254-017-0375-8
_version_ 1783285538561720320
author Haidl, Friederike
Pfister, David
Heidenreich, Axel
Heidegger, Isabel
author_facet Haidl, Friederike
Pfister, David
Heidenreich, Axel
Heidegger, Isabel
author_sort Haidl, Friederike
collection PubMed
description The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice.
format Online
Article
Text
id pubmed-5725505
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-57255052017-12-14 Antiangiogenic therapies in urogenital malignancies: Fiction or fact? Haidl, Friederike Pfister, David Heidenreich, Axel Heidegger, Isabel Memo Review The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice. Springer Vienna 2017-12-04 2017 /pmc/articles/PMC5725505/ /pubmed/29250197 http://dx.doi.org/10.1007/s12254-017-0375-8 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Haidl, Friederike
Pfister, David
Heidenreich, Axel
Heidegger, Isabel
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title_full Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title_fullStr Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title_full_unstemmed Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title_short Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
title_sort antiangiogenic therapies in urogenital malignancies: fiction or fact?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725505/
https://www.ncbi.nlm.nih.gov/pubmed/29250197
http://dx.doi.org/10.1007/s12254-017-0375-8
work_keys_str_mv AT haidlfriederike antiangiogenictherapiesinurogenitalmalignanciesfictionorfact
AT pfisterdavid antiangiogenictherapiesinurogenitalmalignanciesfictionorfact
AT heidenreichaxel antiangiogenictherapiesinurogenitalmalignanciesfictionorfact
AT heideggerisabel antiangiogenictherapiesinurogenitalmalignanciesfictionorfact